Association Of Mean Platelet Volume Research Articles

Association of Mean Platelet Volume with Grades of Hypertensive Retinopathy.

Hypertension is the most prevalent non communicable disease causing deaths even before evidence of target organ damage. Platelet activation is associated with risk of vascular events. Identification of mean platelet volume (MPV) values in patients with hypertensive retinopathy (HR) can help in prognostication and risk stratification of possible complications. Patients presenting to the outpatient department over a period of 18 months underwent clinical examination, blood sampling, direct ophthalmoscopic examination, and two-dimensional echocardiography. Out of 104 subjects, there were a total of 25 females and 79 males. Patients with grade 1HR had a mean MPV value of 9.4, those with grade 2 HR had a mean MPV of 9.8, among people with grade 3 HR the mean MPV was 10.1, and those with grade 4 HR had a mean MPV of 10.9. In our study, we have seen that MPV increases with increasing severity of HR, thus implying that MPV probably plays a role in HR. Testing of MPV can be used to decide whether preventative treatments should be instituted to the prevent the severe complications of retinopathy and thus decrease the risk and occurrence of cardiovascular and cerebrovascular events.

Association of Mean Platelet Volume with Angiographic Thrombus Burden and Short-term Outcome in Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Association of Mean Platelet Volume with Angiographic Thrombus Burden and Short-term Outcome in Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Association of Mean Platelet Volume and Red Cell Distribution Width in Acute Ischemic Stroke

Association of Mean Platelet Volume and Red Cell Distribution Width in Acute Ischemic Stroke

Platelet count as a predictor of thrombotic events following left atrial appendage occlusion: the proof is in the platelet?

Abstract Funding Acknowledgements Type of funding sources: None. Background Patients undergoing left atrial appendage occlusion (LAAO) often are at increased risk for bleeding or thromboembolic events, but no specific risk score for these events in patients after LAAO exists. Concurrently, biomarkers are of growing importance in risk stratification for AF-patients. Therefore, hemostatic biomarkers may have added value in predicting what patients are prone to develop thrombotic and bleeding events and aid in personalizing antithrombotic treatment strategy following LAAO. Methods Six implanting centers retrospectively gathered data on pre-procedural hemostasis markers (i.e. platelet count (PLC), mean platelet volume (MPV), and fibrinogen). Prespecified composite endpoints on thrombotic events (i.e. stroke, transient ischemic attack, systemic embolism and device-related thrombus) and bleeding (major, minor and intracranial hemorrhage) were collected. Results In total, 1315 patients were included (74±9 years, 64% male, 72% Watchman 2.5/FLX, 25% Amplatzer Cardiac Plug/AMULET, 4% other device). Patients were at increased risk for thrombotic and bleeding events with a CHA2DS2-VASc score of 4.3±1.5 and a HAS-BLED score of 3.3±1.1. Baseline data on PLC, MPV, and fibrinogen was available in 92%, 50%, and 21%, respectively. Over a total follow-up duration of 2682 patient years, 111 thrombotic events and 140 bleeding events occurred. Univariate Cox regression analysis showed increased thrombotic risk in patient with higher PLC (HR 1.16 [1.03-1.31] per 50*109 increment), while no statistically significant association with MPV was found (Table 1). Fibrinogen tended to be higher both in patients developing a thrombotic event (HR 1.30 [0.94-1.78] per fL increment) and bleeding event (HR 1.23 [0.98-1.54]). No association of MPV or PLC with bleeding was observed. An optimal PLC cut-off point of 200*109 was identified that was able to decently discriminate between patients developing a thrombotic event and those who did not (Figure 1). Conclusion PLC may be of added value in thrombotic risk stratification following LAAO. Validation of this biomarker by prospective studies and within multivariate prediction models is warranted.

Association of Mean Platelet Volume with Acute Coronary Syndrome: A Case–Control Study

Abstract Background: Acute coronary syndrome (ACS) is a group of symptoms associated with acute myocardial ischemia and is one of the major causes of morbidity and mortality across the world. Its primary etiology is atherosclerosis which is crucially dependent on platelets, and hence, mean platelet volume (MPV) could be a new biomarker for predicting or diagnosing ACS. Our study aims to measure the MPV in patients of ACS and compares it with patients of noncardiac chest pain to evaluate its usefulness as a new marker for ACS. Materials and Methods: A case–control study with 50 cases and 50 controls was carried out in SSG Hospital, Vadodara, over a period of 1 year (November 2016–November 2017). ACS patients were identified according to inclusion and exclusion criteria and their MPV was compared to that of noncardiac chest pain patients. Results: The cases had a higher MPV as compared to the control group, with both males and females being affected, but a stronger association was seen in case of males. Conclusions: Raised MPV has shown significant association with ACS and the test has reasonable sensitivity and specificity, which warrants larger scale studies to confirm its utility as a biomarker for ACS.

Association of Mean Platelet Volume With Vascular Complications in the Patients With Type 2 Diabetes Mellitus.

BackgroundDiabetes mellitus (DM) is a global health concern that is predicted to involve over 10% of the adult population by the next decade. Vascular complications are the major source of mortality and morbidity in diabetics. Mean platelet volume (MPV) which indicates platelet activity may play a crucial role in the vascular effects of DM and, hence, can be used as a prognostic marker. We have attempted to study the association of MPV with the glycemic status, duration of diabetes, and presence of vascular complications in diabetics.MethodsA cross-sectional study of 300 patients with type 2 DM aged ≥18 years admitted to the inpatient department of medicine was carried out in a tertiary care hospital. After subgrouping patients according to their glycemic status and MPV, the association between microvascular and macrovascular complications was studied.ResultsThe majority of patients were >60 years of age and an increasing prevalence of vascular complications was noted with increasing age. Forty-six percent and 45% of the patients had microvascular and macrovascular complications, respectively. Ischemic heart disease (IHD) and retinopathy were the most common macrovascular and microvascular complications, respectively. Vascular complications in DM showed a significant association with MPV, fasting blood sugar (FBS), post-prandial blood sugar (PP2BS), glycated hemoglobin (HbA1c), and the duration of diabetes.ConclusionA high MPV was linked to poor glycemic control, a longer duration of diabetes, and an increased prevalence of vascular complications. Hence, MPV could be used as a cost-effective marker to predict vascular complications in patients with type 2 DM.

Relationship of mean platelet volume to severity of coronary atherosclerosis in non-ST-segment myocardial infarction

Abstract Funding Acknowledgements Type of funding sources: None. Background Platelets play a crucial role in thrombotic mechanism. Mean platelet volume (MPV) is primarily indicator of platelet activation and its measurement is easy and time-effective. The MPV is associated with adverse cardiac events in coronary artery disease. However, limited data are available to assess the relationship of MPV to severity of coronary atherosclerosis through multiple indicators including SYNTAX and GENSINI scores and multivessel disease (MVD) in non-ST-segment elevation myocardial infarction (NSTEMI). Objective We tested the association of MPV to severity of coronary atherosclerosis via multiple indicators in NSTEMI. Methods Ninety-three newly diagnosed NSTEMI patients (male 80.6% male and mean age 60.1 ± 12.3) were prospectively enrolled those who underwent first-time coronary angiography. The MVD defined as having stenosis >70% in >1 coronary vessels and clinical risk scores including SYNTAX and GENSINI were calculated to stratify coronary atherosclerosis severity. These indicators were sub-categorized into low risk (score <23) versus intermediate-high risk (score ³23) SYNTAX and GENSINI scores and MVD versus single vessel disease. The MPV was obtained from complete blood count analysis prior to coronary angiography. Results Patients with intermediate-high risk SYNTAX (P = 0.001) and GENSINI (P = 0.002) scores had higher MPV values as compared to low risk. The higher MPV was also observed in in MPV than single vessel disease (P = 0 .017). The MPV was positively correlated with SYNTAX score (r = 0.281, P = 0.006, Spearmen’s Correlation), GENSINI (r = 0.219, P = 0.035, Spearmen’s Correlation), and MVD (r = 0.243, P = 0.019, Spearmen’s Correlation). Using logistic regression analysis after adjustment of traditional risk factors, we observed MPV remained independently associated with intermediate-high risk SYNTAX [odds ratio (OR): 0.881(95% confidence interval (Cl): 0.247-1.516), P = 0.006) and GENSINI scores [OR: 0.782(95%Cl: 0.131-1.434), P = 0.019) and MVD [OR: 0.718(95%Cl: 0.027-1.409), P = 0.042]. Operating characteristic curves (AUC) for MPV also evaluated intermediate-high SYNTAX score [AUC: 0.696(95%Cl: 0.587-0.804), P = 0.001) and GENSINI score [AUC: 0.694(95%Cl: 0.062-0.851), P = 0.003] and MVD [AUC: 0.660(95% Cl: 0.541-0.779), P = 0.020]. Conclusions We studied a positive relationship of MPV with high coronary severity through multiple indicators including SYNTAX, GENSINI and MVD in NSTEMI patients.

A Study of Association of Mean Platelet Volume with Vascular Complications in Type-2 Diabetes

Background: Type-2 diabetes is considered as a life-long disease which increases morbidity, mortality and decreases the quality of life. Diabetes is a pro-thrombotic state associated with accelerated atherosclerosis and inflammation. MPV is an indicator of the average size and activity of platelets. MPV reflect the state of thrombogenesis deducing an easy way of predicting vascular complications of Type 2 DM and would help in preventing it. Methods: This cross-sectional study was conducted among 110 patients in the hospitals attached to Bangalore Medical College and Research Institute (BMCRI). To assess vascular complications, patients were subjected to fundoscopy, urine examination, 2D echo, ECG, CT scan of brain, doppler of arterial and venous systems. And diabetic neuropathy was evaluated clinically. Statistical analysis was performed using SPSS software. A p value of <0.05 was considered significant. Results: The mean platelet counts and MPV were higher in diabetics with vascular complications compared to those without complications, 9.16 ± 0.86 fl versus 7.7 ± 0.6 fl (P< 0.001), respectively. MPV showed a positive correlation with fasting blood glucose (regression (r) = 0.30)(P=0.0013), post prandial glucose (regression (r) = 0.31)(P=0.0009) and HbA1C levels (regression (r) = 0.26)(P=0.0058) which were significant. Although glycemic status of the patient did not correlate with the duration of diabetes, MPV showed positive correlation with duration of T2DM (regression(r)= 0.19)(P=0.045) which was significant. Conclusion: Our results showed significantly higher MPV in diabetic patients with vascular complications and longer duration. Hence, platelets may play a role and MPV can be used as a simple parameter to assess the vascular events in diabetes.

Association of Mean Platelet Volume (MPV) in Relation to Disease Activity in Lupus

Introduction: Among the various clinical and biochemical parameters which are employed to monitor the disease activity in Systemic Lupus Erythematosus (SLE), Mean Platelet Volume, which is a platelet activation biomarker has been recently studied. We intended at evaluating the MPV in patients with active SLE and comparing it with the same patients who were in clinical remission, and to study the correlation between MPV and SLEDAI. We also studied the correlation between MPV and ESR, complements C3 and C4.&#x0D; Methods: This is a prospective study conducted for a period of 12 months, in which 50 consecutive patients who were recently diagnosed with SLE according to the SLICC classification criteria were included. Complete blood count with MPV levels along with ESR, were measured at the first visit to the hospital and were repeated at every visit till they attained clinical remission. Analysis of MPV was done at first visit and at remission. Complements C3 and C4 was done at the first visit and at remission. The results were then tabulated and statistically analysed using SPSS 25. A Pearson’s correlation test was done to assess the relation between MPV, ESR and SLEDAI.&#x0D; Results: Patients with active disease had a decreased MPV as compared to those in clinical remission (10.91fl, 13.11fl, p=0.011). We observed a weak positive correlation between MPV and SLEDAI (r=0.034, p=0.011). We observed no correlation between MPV and ESR, C3 and C4. Meanwhile, SLEDAI showed a positive correlation with C3 and C4; there was no correlation with ESR though.&#x0D; Conclusion: MPV is reduced in patients with active SLE and displayed an inverse correlation with SLEDAI.

Association of Mean Platelet Volume with Risk Factors and Functional Outcome in Acute Ischemic Stroke.

Background Stroke is the second leading cause of death in the world and a major cause of disability, with ischemic stroke contributing to 87% of all strokes. Platelets are central in the formation of thrombus, and in the process, they enlarge in size, become active, and secrete prothrombotic factors. This is supported by the presence of large platelets in ischemic stroke, where they may be implicated in the pathogenesis of vessel occlusion, leading to stroke. The mean platelet volume (MPV) is an important laboratory marker of platelet function and activation. Materials and Methods The present study was conducted to assess the role of MPV in the pathogenesis, severity, and outcome of ischemic stroke. It was an observational study in 100 acute ischemic stroke (AIS) patients (excluding cardioembolic stroke) admitted to the Medicine wards, Department of Medicine, Jawaharlal Nehru Medical College, a tertiary care hospital at Aligarh. The MPV was correlated with the conventional risk factors of ischemic stroke and outcome (using modified Rankin scale [mRS]). The study revealed statistically significant correlation between MPV and hypertension, type 2 diabetes mellitus, and carotid intima media thickness (CIMT). Also, the MPV at presentation positively correlated with mRS (correlation coefficient 0.818); thus, high MPV was associated with more severe disability. Conclusion The MPV at the time of presentation of ischemic stroke may be useful in predicting the severity of stroke and neurological recovery. However, a larger study including diverse population is required to endorse its predictive value in AIS.

MEAN PLATELET VOLUME AS A PREDICTIVE BIOMARKER FOR RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES

Objective: To determine the association of mean platelet volume with diabetic retinopathy in our population.&#x0D; Study Design: Cross sectional study.&#x0D; Place and Duration of Study: Department of Hematology &amp; Ophthalmology, Combined Military Hospital Lahore, from Jul to Dec 2020.&#x0D; Methodology: A total of 146 known patients with type 2 diabetes were enrolled in this study. They included 78 patients with diabetic retinopathy (group 1) and 68 without diabetic retinopathy (group 2). Five (5ml) of whole blood was extracted from patients through clean venipuncture in a tube containing EDTA and mean platelet volume was generated through automated haematological analyzer Sysmex KX-21 and HbA1c was generated through automated analyzer Cobas c501.&#x0D; Result: A total of 146 patients with type 2 diabetes were included in this study. The age of patients ranged from 25-70 years (Mean age: 53.3 ± 0.02 years). Out of 146 patients 66 (45.2%) were males and 80 (54.8%) were females. Among patients with type 2 diabetes 78 (53.4%) has retinopathy while 68 (46.6%) have no retinopathy. A statistically significant difference (p&lt;0.005) was observed in mean platelet volume and platelet distribution width among patients with retinopathy to those without retinopathy.&#x0D; Conclusion: Mean platelet volume plays a significant role in the determination of retinopathy with type 2 diabetes and helps to monitor progression of disease.

Association of mean platelet volume and platelet distribution width with diabetic retinopathy in patients with diabetes mellitus

Introduction: MPV and PDW are indicators of subclinical platelet hyperactivity and can be used as predictive factors for development and progression of diabetic retinopathy. Materials and Methods: This prospective case control study enrolled 150 patients with diabetic retinopathy (DR group) and 150 diabetic patients without retinopathy (control group). Detailed history and ophthalmic examination was done. The DR group was divided into 5 subgroups according to the ETDRS classification of diabetic retinopathy. MPV, PDW, FBS and PPBS values were obtained. Result: The mean value of MPV in DR group was higher compared to control group (p=0.016). PDW also followed the similar trend with DR group having mean value of 13.71± 1.36 fl and control group having 12.13 ± 1.29 fl (p=0.023). The study also found a trend of increase in severity of diabetic retinopathy with increasing level of MPV and PDW. However a statistically significant association was found only between MPV and stage of diabetic retinopathy (r= 0.214, p= 0.046). A marked increase in MPV and PDW values were found in those with Proliferative diabetic retinopathy (p Conclusion: Platelet indices like MPV can be a cheap and easy to measure tool for monitoring diabetic retinopathy. Keywords: Mean platelet volume, Platelet distribution width, Diabetic retinopathy, Proliferative diabetic retinopathy.

Association of Mean Platelet Volume with Bone Mineral Density in Fibromyalgia

Association of Mean Platelet Volume with Bone Mineral Density in Fibromyalgia

Study of the Relationship Between Mean Platelet Volume and LAD as a Culprit Vessel in NSTEMI

Background: Among acute coronary patients, the ratio of non ST-elevation myocardial infarction (NSTEMI) is increasing and according to recent studies, less than 30% of myocardial infarctions (MIs) are due to ST-elevation myocardial infarction (STEMI). Unlike STEMI, in NSTEMI the ECG is not able to identify the culprit vessel. Objectives: In this study, we aimed to evaluate the association of mean platelet volume (MPV) and NSTEMI due to left anterior descending lesion. Methods: In this cross sectional study 349 patients with NSTEMI were included. Major cardiac risk factors (cigarette, diabetes mellitus (DM), hypertension (HTN), hyperlipidemia (HLP), angiographic findings, and drug history of patients were extracted from patients’ medical files. Then the MPV in complete blood count results and angiography findings were analyzed for any association. According to culprit lesions patients were divided into left anterior descending (LAD) and non-LAD groups. Results: There was a significant difference between the two groups (LAD vs. non-LAD) according to platelet count (P = 0.014), MPV (P = 0.001), HLP (0.024) and DM (0.048). Multivariate regression model has shown the MPV (OR = 0.46, 95%CI = 0.27 - 0.78) and DM (OR = 0.18, 95%CI = 0.06 - 0.54) as independent risk factors for NSTEMI due to LAD lesion. The significant positive correlation was also seen between MPV and left ventricle ejection fraction (LVEF) (r = 0.22, P = 0.006). The area under the curve (AUC) of MPV for predicting LAD culprit lesion was calculated as 69% (P &lt; 0.0001). At cut off point of 9.15, has sensitivity and specificity of MPV for predicting LAD as culprit vessel was 100% and 30% respectively. Conclusions: In NSTEMI patients MPV might be a good tool to differentiate patients with LAD as culprit vessel.

English

English

Platelet Measurements and Type 2 Diabetes: Investigations in Two Population-Based Cohorts.

Type 2 diabetes is a major risk factor for cardiovascular disease. Given the contribution of platelets to atherothrombosis—which in turn is a major contributor to cardiac events, there may be cause to consider platelet function in management of diabetes. Despite the large body of research concerning the role of platelets in cardiovascular complications of type 2 diabetes, evidence from population-based studies of platelet aggregation in diabetes is limited. Mean Platelet Volume (MPV), a cell trait partially associated with markers of platelet activity, is more commonly available. We investigated the association of metabolic syndrome and diabetes with platelet aggregation to three physiological agonists, ADP, collagen, and epinephrine, in the Framingham Heart Study Offspring cohort. We further examined the relationship between MPV measured with Beckman Coulter LH750 instruments and self-reported diabetes as well as MPV and diabetes medication in the UK BioBank cohort, performing the largest such analysis to date. Increased platelet aggregation associated with prevalent diabetes was observed for low concentration epinephrine (0.1 μM) alone and only in analyses of participants stratified either by male sex and/or having metabolic syndrome. Other agonists and concentrations were not significant for prevalent diabetes, or in opposite direction to the main hypothesis (i.e., they showed lower platelet aggregation associated with diabetes). After a median of 18.1 years follow-up, no platelet aggregation trait was associated with increased risk of diabetes (n = 344 cases). As expected, increased MPV was significantly associated with diabetes (β = 0.0976; P = 8.62 × 10−33). Interestingly, sex-stratified analyses indicated the association of MPV with diabetes is markedly stronger in males (β = 0.1232; P = 1.00 × 10−31) than females (β = 0.0514; P = 7.37 × 10−5). Among diabetes medications increased MPV was associated with Insulin (β = 0.1341; P = 1.38 × 10−11) and decreased MPV with both Metformin (β = 0.0763; P = 1.99 × 10−6) as well as the sulphonylureas (β = 0.0559; P = 0.0034). Each drug showed the same direction of effect in both sexes, however, the association with MPV was nearly twice as great or more in women compared to men. In conclusion, platelet function as measured by aggregation to ADP, collagen, or epinephrine does not appear to be consistently associated with diabetes, however, MPV is robustly associated suggesting future work may focus on how MPV segments pre-diabetics and diabetics for risk prediction.

Association of Mean Platelet volume With Angiographic Thrombus Burden In Patient With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutanous Coronary Intervention

Background: ST-elevation myocardial infarction (STEMI) is one of the leading causes of mortality and morbidity worldwide. However, survival after acute STEMI has considerably improved due to increasing symptom recognition, accurate diagnosis and effective timely reperfusion. Objectives: To assess the association of mean platelet volume (MPV) as a biomarker for angiographic thrombus burden in patient with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (PPCI). Patients and methods: This study was conducted on 125 patients admitted to El-Mokatem health insurance hospital, with the diagnosis of acute ST-segment elevation myocardial infarction (STEMI) treated with PPCI in the period between December 2018 and October 2019. Results: Thrombus burden level determined by TIMI thrombus grade (TIMITG) was significantly higher in the high MPV group (p-value 9.75 predicted LTB with 83.3% sensitivity and 86.2% specificity. Multivariate logistic regression analysis demonstrated MPV was an independent predictor of large intracoronary thrombus burden in patients with STEMI undergoing PPCI Conclusion: In STEMI patients who underwent PPCI, MPV on admission was significantly higher in those who experienced high thrombus burden. MPV on admission may serve as a readily available an independent predictor of the thrombus burden in STEMI patients undergoing PPCI. Keywords: Mean Platelet volume, TIMITG, HTB, PCI, PPCI, STEMI

The association of mean platelet volume to lymphocyte ratio and noreflow in patients with myocardial infarction undergoing primary percutaneous coronary intervention

Introduction: The acute coronary events are one of the most common problems which are accounted to higher mortality and morbidity rate around the world. The underlying mechanism is related to occlusion, and the best therapy is to reopen the affected vessels. Many factors can influence the outcomes of percutaneous coronary intervention (PCI). Methods: This cross-sectional study was conducted on 845 cases with acute myocardial infarction (AMI) undergoing PCI for evaluation of the "No-Reflow" phenomenon who were referred to Shahid Madani hospital in 2018. All demographic, laboratory and angiographic studies were evaluated. The obtained data were recorded and analyzed by SPSS 21. Results: Among 845 patients with STEMI, the incidence of angiographic no-reflow was 28% (n = 245). The older cases with co-morbid diseases and cardiac-related risk factors were considered as vulnerable to no-reflow after PCI. The other parameters were partially decisive factors for the prediction of no-reflow and mortality rate, such as higher MPV and MPV to lymphocyte ratio. Conclusion: The coronary artery involvement is a troublesome event because of the established heart risk factors, and sometimes treating it with PCI could be complicated due to no-reflow. The simple predictors (i.e., MPV to lymphocyte ratio) could help us reduce morbidity and mortality.

Association of mean platelet volume with angiographic thrombus burden and short-term outcome in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

Abstract Background Coronary artery disease (CAD) represents a leading cause of death worldwide. Given it adverse prognosis, risk stratification of patients with an acute coronary syndrome (ACS) remains a challenging issue. In this regard, different biomarkers are becoming more and more important in the diagnosis, assessment and outcome prediction. For the development of atherothrombosis, platelets have a huge part to play. Mean platelet volume (MPV), a unique measure of platelet size, is an indicator of platelet reactivity and suggests that MPV could be a biomarker of the risk and prognosis of patients with STEMI. Aim and Objectives:to test the predictive value of MPV for angiographic thrombus burden and short term outcomes in patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Patients and Methods all patients presented with acute STEMI to the cardiology department of Ain Shams university hospitals, with Pain to door time less than 12 hours and underwent PPCI. MPV was measured on admission. Angiographic thrombus burden and post interventional thrombolysis in myocardial infarction (TIMI) flow grade and myocardial blush grade (MBG) were recorded. Patients were followed up for 3 to 6 months. Results This study included 72 patients with STEMI who underwent PPCI. The patients’ ages ranged between 33 and 73 years old (mean age 53.22 ± 9.96years). This study included 62 males and 10 females. The MPV of the studied cases was 9.97 ± 1.31 fl. MPV was higher among patients with HTB (11.42±1.007 vs. 9.53±1.039.P 0.00) and patients with (MBG (0-1) and TIMI flow&amp;gt;3) (10.59±1.839vs. 9.81±1.092, P 0.004 and 10.49±1.191vs. 9.81±1.309, P 0.04 respectively).with short term follow up12 patients had heart failure requiring hospitalization and they had a higher MPV (10.81 ± 1.21 vs. 9.74 ± 1.3, p 0.01). In binary logistic regression analysis, the MPV was an independent predictor of TG after STEMI (odds ratio 7.278, and P value (0.000), CI (2.518-21.036)). Conclusion MPV may be a useful biomarker that can help in identification of higher-risk patients with large intracoronary thrombus burden, who might require more potent antiplatelet therapy.

Abstract WMP56: Association of Mean Platelet Volume and Its Genetic Variants With Stroke Severity and One-year Mortality in a Polish Stroke Cohort

Background: Increased mean platelet volume (MPV) is a marker of worse outcomes in cardiovascular disorders, however its prognostic role in patents with ischemic stroke and possible genetic underpinnings remains uncertain. We aimed to determine whether MPV and selected single nucleotide polymorphisms (SNPs) that have been associated with MPV in genome-wide association studies (GWAS) relate to stroke severity, functional outcome on discharge, and one-year mortality in patients with ischemic stroke. Methods: We retrospectively analyzed 577 patients with first ever ischemic stroke. Genotyping of 3 SNPs (rs342293, rs1354034, rs7961894) was performed using a real-time polymerase chain reaction allelic discrimination assay. Multivariable regression was used to determine the association of MPV and MPV-associated SNPs with the National Institutes of Health Stroke Scale (NIHSS) score on admission, modified Rankin Scale (mRS) on discharge, and data on one-year mortality. Results: Rs7961894, but not rs342293 and rs1354034 SNP, was independently associated with MPV in the highest quartile (MPV Q4). MPV Q4 was associated with significantly greater admission NIHSS (p=0.004), poor discharge outcome (p=0.034), and worse one-year mortality (p=0.033). After adjustment for pertinent covariates, MPV Q4 remained independently associated with a greater admission NIHSS score (p=0.025). Patients carrying T&gt;C variant of rs7961894 SNP had a significantly lower one-year mortality as compared to patients with CC genotype (p=0.029; Log-Rank test; Fig.1) and T&gt;C variant of rs7961894 SNP remained an independent marker of a lower one-year mortality (HR=0.30; 95%CI:0.13-0.70; p=0.006) in the studied population. Conclusion: MPV is a marker of stroke severity and rs7961894 is independently associated with MPV in acute phase of ischemic stroke and relates to one-year mortality after stroke.